STOCK TITAN

Scholar Rock Holding Corporation - SRRK STOCK NEWS

Welcome to our dedicated page for Scholar Rock Holding Corporation news (Ticker: SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding Corporation stock.

Scholar Rock Holding Corporation (SRRK) is a biotechnology company dedicated to pioneering a novel class of biologic therapies known as 'niche modulators'. These therapies selectively target the activation of growth factors within the disease microenvironment, offering a groundbreaking approach to treating serious medical conditions. Scholar Rock's initial proprietary and partnered drug discovery programs focus on specific growth factors, particularly members of the TGF-beta superfamily, which are critical in regulating cell growth and differentiation. These growth factors are notably present in the microenvironments of significant diseases like fibrosis, musculoskeletal disorders, and autoimmune diseases.

The company’s innovative therapeutic strategy stems from the foundational scientific discoveries of its founders, Professors Timothy Springer, PhD, and Leonard Zon, MD, from Children's Hospital Boston and Harvard Medical School. These discoveries illuminate the molecular mechanisms of growth factor activation, empowering Scholar Rock to advance its ground-breaking treatments.

Scholar Rock is backed by a consortium of top-tier life sciences investors, including Polaris Partners and Arch Venture Partners. Its flagship product candidate, Apitegroma, is a selective, fully human, monoclonal antibody that inhibits the activation of the growth factor myostatin in skeletal muscle. This innovative mechanism holds promise for treating neuromuscular disorders. Another key product in the company's pipeline is SRK-181, which targets the activation of latent transforming growth factor beta-1 (TGFβ1) and is being developed to treat cancers that are resistant to existing anti-PD-(L)1 antibody therapies.

With its operations based in the United States, Scholar Rock continues to make significant strides in the biopharmaceutical industry, pushing the envelope of medical science and offering hope for effective treatments against some of the most challenging diseases.

Rhea-AI Summary
Scholar Rock (NASDAQ: SRRK) to present at J.P. Morgan 42nd Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
conferences
-
Rhea-AI Summary
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards covering 78,576 shares of its common stock to 6 newly hired employees. The awards include stock options to purchase 44,900 shares and restricted stock units (RSUs) for 33,676 shares. The options have an exercise price of $18.07 and will vest over time. The awards are subject to the 2022 Inducement Equity Plan and the company's board of directors' approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
management
-
Rhea-AI Summary
Scholar Rock (NASDAQ: SRRK) Grants Inducement Equity Awards to Newly Hired Employee - Scholar Rock, a Phase 3, clinical-stage biopharmaceutical company, has announced the granting of inducement equity awards to a newly hired employee. The awards include stock options and restricted stock units, subject to the terms and conditions of the 2022 Inducement Equity Plan. The options have an exercise price of $9.88, vesting over time, while the RSUs will vest in four equal annual installments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
management
Rhea-AI Summary
Scholar Rock (NASDAQ: SRRK) reported completing enrollment for the pivotal Phase 3 SAPPHIRE trial evaluating apitegromab, with topline data expected in 4Q 2024. They also announced expansion into cardiometabolic disorders with SRK-439 and presented new data supporting proof of concept for SRK-181. Additionally, they completed a $98 million public offering, extending projected cash runway into the second half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
-
Rhea-AI Summary
Scholar Rock announces promising anti-tumor activity in patients with clear cell renal cell carcinoma (ccRCC) in its Phase 1 DRAGON trial of SRK-181. The objective response rate (ORR) was 21.4% and the disease control rate (DCR) was 57%. Biomarker data supports proof of mechanism across multiple tumor types. Safety data shows SRK-181 is generally well tolerated. The company will discuss the SRK-181 program during a conference call on November 7th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
-
Rhea-AI Summary
Scholar Rock, a clinical-stage biopharmaceutical company, will participate in upcoming investor conferences: Truist Securities BioPharma Symposium on November 9, 2023, and Piper Sandler 35th Annual Healthcare Conference on November 28, 2023. A live webcast of the Piper Sandler event will be available on the Scholar Rock website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
conferences
Rhea-AI Summary
Scholar Rock to host conference call to discuss Q3 2023 financial results and business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
conferences earnings
-
Rhea-AI Summary
Scholar Rock to present data from the DRAGON trial at the Society for Immunotherapy of Cancer Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
conferences clinical trial
-
Rhea-AI Summary
Scholar Rock announces the closing of its underwritten public offering, raising approximately $97.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
Rhea-AI Summary
Scholar Rock Holding Corporation announces pricing of upsized public offering of common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.66%
Tags

FAQ

What is the current stock price of Scholar Rock Holding Corporation (SRRK)?

The current stock price of Scholar Rock Holding Corporation (SRRK) is $44.78 as of December 20, 2024.

What is the market cap of Scholar Rock Holding Corporation (SRRK)?

The market cap of Scholar Rock Holding Corporation (SRRK) is approximately 4.1B.

What is Scholar Rock Holding Corporation's main focus?

Scholar Rock focuses on discovering and developing niche modulators that target growth factors in disease microenvironments for treating serious diseases.

What are niche modulators?

Niche modulators are biologic therapies that selectively target the activation of growth factors within the disease microenvironment.

Who founded Scholar Rock?

Scholar Rock was founded by Professors Timothy Springer, PhD, and Leonard Zon, MD, from Children's Hospital Boston and Harvard Medical School.

What is Apitegroma?

Apitegroma is a selective, fully human, monoclonal antibody developed by Scholar Rock to inhibit the activation of myostatin in skeletal muscle.

What diseases does Scholar Rock target?

Scholar Rock targets diseases such as neuromuscular disorders, cancer, fibrosis, and autoimmune diseases.

What is SRK-181?

SRK-181 is a product candidate that inhibits the activation of latent TGFβ1 and is being developed to treat cancers resistant to anti-PD-(L)1 therapies.

Who are some of Scholar Rock's investors?

Scholar Rock is backed by investors such as Polaris Partners and Arch Venture Partners.

Where is Scholar Rock based?

Scholar Rock operates in the United States.

What is the therapeutic approach of Scholar Rock?

The company's approach is based on targeting the activation of growth factors, specifically within the disease microenvironment, to treat serious conditions.

What recent achievements has Scholar Rock made?

Scholar Rock has advanced its product candidates, Apitegroma and SRK-181, showing promising therapeutic potential for treating serious diseases.

Scholar Rock Holding Corporation

Nasdaq:SRRK

SRRK Rankings

SRRK Stock Data

4.05B
91.72M
1.07%
98.55%
16.18%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE